Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer
A novel drug combination led to clinically meaningful antitumor activity in metastatic ESR1-mutated, estrogen receptor-positive (ER+)/HER2-negative breast cancer that had progressed on CDK4/6 inhibition, a small prospective study showed. Adding the selective estrogen receptor modulator (SERM) lasofoxifene to abemaciclib (Verzenio) resulted in a median progression-free survival (PFS) of 56 weeks, and a 24-week clinical benefit […]
Pembrolizumab Active in BCG-Unresponsive Papillary High-Risk Bladder Cancer
SAN FRANCISCO — Pembrolizumab (Keytruda) monotherapy showed encouraging antitumor activity in patients with papillary high-risk non-muscle-invasive bladder cancer (HR NMIBC) that was unresponsive to Bacillus Calmette-Guerin (BCG) treatment. In a cohort of patients in the KEYNOTE-057 study who had 45 months of follow-up, those treated with pembrolizumab (n=32) had an estimated 12-month disease-free survival (DFS) […]
Adagrasib Shows Anti-Tumor Activity in Heavily Pretreated KRAS-Mutant CRC
Adagrasib (Krazati) demonstrated antitumor activity in heavily pretreated patients with KRAS G12C-mutated, metastatic colorectal cancer (CRC), according to phase I/II study results. Monotherapy with the oral KRAS inhibitor led to responses in 19% (95% CI 8-33) of 43 evaluable patients with CRC, with a median duration of response of 4.3 months (95% CI 2.3-8.3) and […]
Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boost
CHICAGO — Randomized data suggest that an anti-angiogenic agent can kick-start immunotherapy’s antitumor activity in non-small cell lung cancer (NSCLC) patients whose disease has already progressed after chemotherapy and a checkpoint inhibitor. In the phase II study, median overall survival improved by nearly 3 months with ramucirumab (Cyramza) plus pembrolizumab (Keytruda) versus standard-of-care options (14.5 […]